Tag: Genetics
Results from Phase I Trial with SGN-CD19A Shows Encouraging Anti-tumor Activity...
esults from an interim phase I clinical trial presented at the 50th Annual Meeting of the American Association of Clinical Oncology (ASCO), being held May 30 - June 3, 2014 in Chicago, Ill, shows that SGN-CD19A (Seattle Genetics, Inc, Bothell, WA 98021, USA), an antibody-drug conjugate or ADC in development for the treatment of B-cell malignancies, offers encouraging anti-tumore activity in patients with Non-Hodgkin Lymphoma (NHL).[1]
Pfizer and Seattle Genetics Agree on Antibody-Drug Conjugate Collaboration
Pfizer and Seattle Genetics, a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer ,...
Brentuximab Offers Promising New Treatment Option for Patients with Relapsed or...
While 70 to 80% of all newly diagnosed patients with adult Hodgkin lymphoma are typically cured with combination chemotherapy of three or four agents...
